BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
BRKR - Bruker Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$50.13
DETAILS
HIGH:
$60.00
LOW:
$35.00
MEDIAN:
$51.50
CONSENSUS:
$50.13
UPSIDE:
9.72%
Stock News
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker (BRKR) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.47 per share a year ago.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bi.
Bruker Corp (BRKR) Shares Fall 5.4% -- What GF Score of 81 Tells Investors
On April 29, 2026, Bruker Corp (BRKR) shares fell 5.4% to $34.29, continuing a downward trend that has seen a 27.1% decline year-to-date. The stock has traded w
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta.
A Look at Bruker Corp (BRKR) After 4.5% Gain -- GF Value $71.47 vs Price $40.70
On April 17, 2026, Bruker Corp (BRKR) shares rose 4.5% today, bringing the current price to $40.70. The stock has experienced a 52-week range of $28.53 to $56.2
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx.
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati.
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker's continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w.
Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and da.
Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue to shrink and systems become increasingly more complex. As the largest supplier of nanoscale infrared (nanoIR) spectroscopy technology to the semiconductor industry, Bruker is expanding the use of AFM-IR beyond its established role in nano.
Allspring Global Investments Holdings LLC Boosts Position in Bruker Corporation $BRKR
Allspring Global Investments Holdings LLC boosted its holdings in Bruker Corporation (NASDAQ: BRKR) by 38.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 255,441 shares of the medical research company's stock after purchasing an additional 70,541 shares during the quarter. Allspring
Should You Continue to Retain Bruker Stock in Your Portfolio?
BRKR faces macro and currency headwinds, but strong BSI Nano growth, AI-driven demand and BioSpin innovations support its long-term outlook.
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: “Bruker is delighted that Thierry is joining our Board. I have admired his su.
Bruker Corporation (NASDAQ:BRKR) Receives Consensus Rating of “Hold” from Brokerages
Bruker Corporation (NASDAQ: BRKR - Get Free Report) has earned an average rating of "Hold" from the fifteen analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy
Bruker Corporation $BRKR Shares Purchased by Aquatic Capital Management LLC
Aquatic Capital Management LLC raised its holdings in shares of Bruker Corporation (NASDAQ: BRKR) by 120.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,596 shares of the medical research company's stock after buying an additional
Citigroup Inc. Sells 29,083 Shares of Bruker Corporation $BRKR
Citigroup Inc. trimmed its stake in shares of Bruker Corporation (NASDAQ: BRKR) by 32.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,838 shares of the medical research company's stock after selling 29,083 shares during the quarter. Citigroup Inc.'s holdings in
DNB Asset Management AS Increases Stake in Bruker Corporation $BRKR
DNB Asset Management AS grew its holdings in Bruker Corporation (NASDAQ: BRKR) by 40.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,257 shares of the medical research company's stock after acquiring an additional 41,289 shares during the period. DNB
Price Targets
Bruker price target raised to $45 from $40 at Stifel
$45.00
(was $43.73)
Daniel Arias
·
Stifel Nicolaus
Bruker price target raised to $45 from $40 at UBS
$45.00
(was $42.30)
UBS
Bruker price target raised to $53 from $45 at Barclays
$53.00
(was $42.30)
Luke Sergott
·
Barclays
Bruker price target lowered to $35 from $40 at Goldman Sachs
$35.00
(was $37.19)
Evie Koslosky
·
Goldman Sachs
Bruker price target raised to $49 from $43 at UBS
$49.00
(was $36.99)
UBS
Bruker price target lowered to $50 from $55 at Barclays
$50.00
(was $37.51)
Luke Sergott
·
Barclays
Bruker price target lowered to $50 from $55 at Jefferies
$50.00
(was $37.51)
Jefferies
Bruker price target raised to $58 from $53 at Guggenheim
$58.00
(was $49.02)
Guggenheim
Bruker price target raised to $53 from $45 at Guggenheim
$53.00
(was $49.87)
Subbu Nambi
·
Guggenheim
Bruker price target raised to $55 from $48 at Wells Fargo
$55.00
(was $45.12)
Brandon Couillard
·
Wells Fargo
Bruker price target raised to $55 from $45 at Barclays
$55.00
(was $45.12)
Barclays
Wolfe upgrades Bruker to Outperform on 2026 growth
$60.00
(was $47.65)
Wolfe Research
Bruker initiated with a Sell at Goldman Sachs
$40.00
(was $46.00)
Goldman Sachs
Bruker initiated with a Buy at Rothschild & Co Redburn
$60.00
(was $43.39)
Redburn Partners
Bruker price target raised to $43 from $40 at UBS
$43.00
(was $38.71)
UBS
Bruker price target raised to $45 from $40 at Barclays
$45.00
(was $38.71)
Barclays
Bruker price target lowered to $40 from $43 at Barclays
$40.00
(was $34.72)
Barclays
Bruker price target lowered to $40 from $48 at Stifel
$40.00
(was $32.07)
Daniel Arias
·
Stifel Nicolaus
Bruker price target lowered to $43 from $46 at Barclays
$43.00
(was $34.72)
Luke Sergott
·
Barclays
Bruker price target lowered to $60 from $70 at Jefferies
$60.00
(was $34.72)
Jefferies